VIELA BIO, INC. This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Viela Bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for severe inflammation and autoimmune diseases. Its product pipeline includes Inebilizumab, VIB4920 and VIB7734. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. VIB4920 is a fusion protein designed to bind to CD40 ligand (CD40L) on activated T cells, blocking the interaction with CD40 expressed on B cells and preventing them from differentiating into plasma cells and memory B cells. VIB7734 is a treatment for autoimmune and related inflammatory diseases.
| 1st Jan change | Capi. | |
|---|---|---|
| -2.72% | 102B | |
| +2.21% | 96.09B | |
| +2.13% | 22.28B | |
| -17.09% | 21.4B | |
| -8.79% | 18.14B | |
| -39.98% | 17.02B | |
| -13.94% | 16.09B | |
| +6.12% | 13.83B | |
| +32.06% | 11.97B |
